Rana JS, Dunning A, Achenbach S et al (2012) Differences in prevalence, extent, severity, and prognosis of coronary artery disease among patients with and without diabetes undergoing coronary computed tomography angiography: results from 10,110 individuals from the CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes): an InteRnational Multicenter Registry. Diabetes Care 35:1787–1794
Article
PubMed
PubMed Central
Google Scholar
Verma S, Farkouh ME, Yanagawa B et al (2013) Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 1:317–328
Article
PubMed
Google Scholar
Ryden L, Grant PJ, Anker SD et al (2013) ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34:3035–3087
Article
PubMed
Google Scholar
Farkouh ME, Domanski M, Sleeper LA et al (2012) Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 367:2375–2384
Article
PubMed
CAS
Google Scholar
Kappetein AP, Head SJ, Morice MC et al (2013) Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. Eur J Cardiothorac Surg 43:1006–1013
Article
PubMed
Google Scholar
Moreyra AE, Deng Y, Wilson AC, Cosgrove NM, Kostis WJ, Kostis JB (2013) Incidence and trends of heart failure admissions after coronary artery bypass grafting surgery. Eur J Heart Fail 15:46–53
Article
PubMed
Google Scholar
U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. Guidance for Industry. Diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Available from www.fda.gov/downloads/Drugs/Guidances/ucm071627.pdf. Accessed 9 Jan 2018
Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128
Article
PubMed
CAS
Google Scholar
Boehringer Ingelheim. Jardiance® (empagliflozin) tablets prescribing information. Available from http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Jardiance/jardiance.pdf. Accessed 9 Jan 2018
American Diabetes Association (2017) Pharmacologic approaches to glycemic treatment. Sec. 8. In Standards of Medical Care in Diabetes—2017. Diabetes Care 40(Suppl 1):S64–S74
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee (2016) Pharmacologic management of type 2 diabetes: 2016 interim update. Can J Diabetes 40:484–486
Article
Google Scholar
Okrainec K, Platt R, Pilote L, Eisenberg MJ (2005) Cardiac medical therapy in patients after undergoing coronary artery bypass graft surgery: a review of randomized controlled trials. J Am Coll Cardiol 45:177–184
Article
PubMed
Google Scholar
Rouleau JL, Warnica WJ, Baillot R et al (2008) Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery. Circulation 117:24–31
Article
PubMed
CAS
Google Scholar
Fitchett D, Zinman B, Wanner C et al (2016) Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J 37:1526–1534
Article
PubMed
PubMed Central
CAS
Google Scholar
Mancini GBJ, Farkouh M, Verma S (2017) Revascularization for patients with diabetes mellitus and stable ischemic heart disease: an update. Curr Opin Cardiol 32:608–616
Article
PubMed
Google Scholar
Seferovic PM, Paulus WJ (2015) Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J 36:1718–1727
Article
PubMed
Google Scholar
Ledru F, Ducimetiere P, Battaglia S et al (2001) New diagnostic criteria for diabetes and coronary artery disease: insights from an angiographic study. J Am Coll Cardiol 37:1543–1550
Article
PubMed
CAS
Google Scholar
Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ (2016) Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134:752–772
Article
PubMed
CAS
Google Scholar
Verma S, McMurray JJV, Cherney DZI (2017) The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure. JAMA Cardiol 2:939–940
Article
PubMed
Google Scholar
Heise T, Jordan J, Wanner C et al (2016) Acute pharmacodynamic effects of empagliflozin with and without diuretics in patients with type 2 diabetes. Clin Ther 38:2248–2264
Article
PubMed
CAS
Google Scholar
Heise T, Jordan J, Wanner C et al (2016) Pharmacodynamic effects of single and multiple doses of empagliflozin in patients with type 2 diabetes. Clin Ther 38:2265–2276
Article
PubMed
CAS
Google Scholar
Sattar N, McLaren J, Kristensen SL, Preiss D, McMurray JJ (2016) SGLT2 inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms? Diabetologia 59:1333–1339
Article
PubMed
PubMed Central
Google Scholar
Verma S, Garg A, Yan AT et al (2016) Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial? Diabetes Care 39:e212–e213
Article
PubMed
Google Scholar
Byrne NJ, Parajuli N, Levasseur JL et al (2017) Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure. JACC Basic Transl Sci 2:347–354
Article
PubMed
PubMed Central
Google Scholar
Shi X, Verma S, Yun J et al (2017) Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial? Mol Cell Biochem 433:97–102
Article
PubMed
CAS
Google Scholar
Lopaschuk GD, Verma S (2016) Empagliflozin’s fuel hypothesis: not so soon. Cell Metab 24:200–202
Article
PubMed
CAS
Google Scholar
Baartscheer A, Schumacher CA, Wust RC et al (2017) Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia 60:568–573
Article
PubMed
CAS
Google Scholar
Wanner C, Inzucchi SE, Lachin JM et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375:323–334
Article
PubMed
CAS
Google Scholar
Cherney DZI, Zinman B, Inzucchi SE et al (2017) Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 5:610–621
Article
PubMed
CAS
Google Scholar
Cherney DZ, Perkins BA, Soleymanlou N et al (2014) Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129:587–597
Article
PubMed
CAS
Google Scholar
Boehringer Ingelheim. Empagliflozin (Jardiance®) to be studied in chronic kidney disease. Available from www.boehringer-ingelheim.com/press-release/empagliflozin-be-studied-chronic-kidney-disease. Accessed 9 Jan 2018
Kulik A, Ruel M, Jneid H et al (2015) Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. Circulation 131:927–964
Article
PubMed
Google Scholar
Inzucchi SE, Iliev H, Pfarr E, Zinman B (2018) Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial. Diabetes Care 41:e4–e5
Article
PubMed
Google Scholar
Verma S, Mazer CD, Al-Omran M et al (2018) Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME. Circulation 137:405–407
Article
PubMed
Google Scholar